| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2016: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2015: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2012: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Outline of Final Research Achievements |
We performed in vitro and in vivo MRI experiments with Mn2+ to investigate whether manganese-enhanced MRI (MEMRI) can be used to detect cell alterations as an early-phase tumor response after radiotherapy. MEMRI was successfully used to detect cell alterations as an early-phase cellular response after tumor radiotherapy (Cancer Res. 2013). Also, we reported an nano-MRI contrast agent that rapidly amplifies MRI signals in response to pH. We confined Mn2+ within pH-sensitive calcium phosphate (CaP) nanoparticles. At a low pH, such as in solid tumors, the CaP disintegrates and releases Mn2+. Binding to proteins increases the relaxivity of Mn2+ and enhances the contrast. We show that these nanoparticles could rapidly and selectively enhanced solid tumors, identify low pH regions within the tumor (Nat Nanotechnol. 2016).
|
